Technology
Health
Pharmaceutical

Akari Therapeutics

$2.76
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-6.12%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AKTX and other stocks, options, ETFs, and crypto commission-free!

About

Akari Therapeutics Plc ADR, also called Akari Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. Read More The company was founded on October 7, 2004 and is headquartered in London, the United Kingdom.

Employees
14
Headquarters
London, London & South East
Founded
2004
Market Cap
43.63M
Price-Earnings Ratio
Dividend Yield
Average Volume
658.01K
High Today
$2.97
Low Today
$2.75
Open Price
$2.95
Volume
59.02K
52 Week High
$9.20
52 Week Low
$1.56

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
Biopharmaceutical
2015 IPO
UK

News

Yahoo FinanceApr 23

Akari Reports Fourth Quarter and Full Year 2018 Financial Results and Business Highlights

Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease Area Index (BPDAI) score and blistering in ongoing Phase II clinical trial Pivotal clinical trial for pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) expected to start Q4 2019 Initial data on atopic keratoconjunctivitis (AKC) and pre-clinical back of the eye program to be presented at As...

543

Earnings

-$0.66
-$0.44
-$0.22
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Sep 26, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.